Fierce Pharma

FEBRUARY 12, 2024

Eohilia, an oral suspension formulation of the corticosteroid budesonide, has surprisingly won over the FDA even after the drug’s developer, Takeda, had at one point abandoned the program following | Takeda's Eohilia has surprisingly won over the FDA even after the company had at one point abandoned the program following an FDA rejection. But the first FDA-approved oral eosinophilic esophagitis therapy comes with a limitation.

FDA 284

FDA 284

Pharmaceutical Technology

FEBRUARY 12, 2024

The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5 vaccine targeting Omicron variant.

142

142

Fierce Pharma

FEBRUARY 12, 2024

After a series of regulatory setbacks in Europe, PTC Therapeutics will soon find itself under a generic attack in the U.S. | After a series of regulatory setbacks in Europe, PTC Therapeutics will soon find itself under a generic attack in the U.S.

FDA 277

FDA 277

pharmaphorum

FEBRUARY 12, 2024

Medicxi has combined six biotechs with dermatology medicines in development in a single drugmaker, called Alys Pharma, which starts life with $100 million in financing.

Pharma 120

Pharma Medicine 120

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

FEBRUARY 12, 2024

With a patent feud settled and its approval application back at the FDA’s desk, Sweden’s Xspray Pharma believes it's on track to launch its first commercial product late this summer. | Following a rejection in 2023, the FDA has accepted the resubmission of Xspray’s application for its leukemia candidate Dasynoc, which is seeking to dethrone Bristol Myers Squibb’s entrenched cancer blockbuster Sprycel (dasatinib).

FDA 263

FDA Pharma 263

MedCity News

FEBRUARY 12, 2024

By leveraging AI and machine learning, researchers can analyze complex data sets, identify novel biomarkers, and provide more effective and tailored treatment options for cancer patients.

Patients 115

Patients Medicine Biopharma 115

MedCity News

FEBRUARY 12, 2024

The Payer Insights Program at ViVE 2024, in partnership with MedCity News, kicks off day one at the event. This new immersive program will focus on the impact of rising healthcare costs, recent regulatory changes, and innovative payer solutions for optimizing data insights, minimizing costs, and expanding access to care.

Healthcare 110

Healthcare Healthcare 110

Fierce Pharma

FEBRUARY 12, 2024

Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starti | Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting to take shape.

Pharmaceutical 251

Pharmaceutical 251

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 112

FDA Leads Pharmaceutical Patients 112

Fierce Pharma

FEBRUARY 12, 2024

AbbVie has closed its $10.1 billion buyout of antibody-drug conjugate specialist ImmunoGen. | AbbVie has closed its $10.1 billion buyout of antibody-drug conjugate specialist ImmunoGen. And the good news from an industry perspective is that deal took less than three months to complete.

167

167

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

PM360

FEBRUARY 12, 2024

This February we celebrate the 16th annual Rare Disease Day , established in 2008, to raise awareness of the more than 7,000 identified rare diseases worldwide. Rare Disease Day is observed annually on the “rarest” day of the year, February 28th or 29th depending on leap years. Created by The European Organization for Rare Diseases (EURORDIS) , this globally coordinated event brings together industry stakeholders to advocate for increased access to medical treatment for patients, caregivers, and

Food and Drug Administration 105

Food and Drug Administration Patients Medical Networking 105

MedCity News

FEBRUARY 12, 2024

Today, many hope artificial intelligence will be the key that unlocks the value of digitization. Perhaps it will, but the claim that better technology will necessarily improve healthcare is no longer credible. Having lived in both analog and digital worlds, who better than us Oregon Trail doctors to help ensure digital health technologies best serve our workforce, patients, and communities?

Doctors 106

Doctors Healthcare Healthcare Patients 106

pharmaphorum

FEBRUARY 12, 2024

Study finds that monitoring of rheumatoid arthritis patients with an Apple Watch and iPhone and AI algorithm improves on standard practices.

Patients 116

Patients 116

MedCity News

FEBRUARY 12, 2024

Who do the California Office of Healthcare Affordability’s cost and market impact review regulations apply to? That depends on three questions, according to a recent webinar.

Healthcare 108

Healthcare Healthcare Marketing 108

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

European Pharmaceutical Review

FEBRUARY 12, 2024

Bringing a therapeutic to market is a long and complex process. ‘From bench to bedside’ is a well-known aphorism that merely hints at the arduous journey drug treatments must undergo from their position as a candidate molecule or soon to be explored pathway, to becoming a tablet, injection, or infusion administered to patients worldwide. The scientific rigour of development and the various regulatory hurdles involved mark most of that journey.

Manufacturing 98

Manufacturing Medicine Leads Patients 98

MedCity News

FEBRUARY 12, 2024

Private equity is a way to help achieve scale. Groups that use scale to better serve the stakeholders that matter most, including radiologists, hospitals, referring physicians and—most importantly—patients, will be best positioned to not just survive, but thrive.

Physicians 105

Physicians Patients Healthcare Healthcare 105

European Pharmaceutical Review

FEBRUARY 12, 2024

Researchers based in France have demonstrated a robust online Raman monitoring model for bioreactors, which combines Raman spectroscopy and machine learning (ML). In the study, the fermentation of alcohol by Saccharomyces cerevisiae ( S. cerevisiae) was used as a benchmark bioprocess. The method was validated across numerous batches and a fed-batch bioreactor.

Pharmaceutical 97

Pharmaceutical Management 97

pharmaphorum

FEBRUARY 12, 2024

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for primary biliary cholangitis (PBC) for $4.

104

104

Advertisement

MedCity News

FEBRUARY 12, 2024

With the many advantages of robotics, it is time for pediatric patients to garner the same attention and technology development that adult patients have benefitted from for decades.

Patients 100

Patients Physicians 100

pharmaphorum

FEBRUARY 12, 2024

GSK’s antisense-based drug for chronic hepatitis B, bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval

FDA 107

FDA 107

MedCity News

FEBRUARY 12, 2024

Acquiring CymaBay Therapeutics gives Gilead Sciences another drug for its liver disease portfolio. CymaBay’s molecule, seladelpar, is under FDA review for treating primary biliary cholangitis, a rare disease affecting the bile ducts of the liver.

FDA 101

FDA Biopharma Pharma 101

pharmaphorum

FEBRUARY 12, 2024

Biotech giant CSL has seen almost 5% wiped off the value of its shares after one of its most anticipated pipeline products failed a phase 3 trial in heart attack patients

Patients 95

Patients 95

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

FEBRUARY 12, 2024

Adopting consumer strategies from leading retailers can give MA plans an edge in an increasingly competitive market filled with new entities while improving quality, reducing cost, and improving member loyalty.

Retail 89

Retail Management Competition Leads 89

Pharmaceutical Technology

FEBRUARY 12, 2024

The humanised monoclonal antibody DISC-3405 is under investigation in a Phase I clinical trial, with data expected this year.

95

95

PharmaTimes

FEBRUARY 12, 2024

The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359

Safety 113

Safety Patients Healthcare Healthcare 113

pharmaphorum

FEBRUARY 12, 2024

At its second attempt, Takeda has won FDA approval for Eohilia, the first and only oral therapy in the US for eosinophilic oesophagitis

FDA 75

FDA 75

Advertisement

Distribution

PharmaTimes

FEBRUARY 12, 2024

The chip removes cells, which could become tumours, before they are implanted in a patient

Patients 102

Patients 102

PharmaVoice

FEBRUARY 12, 2024

Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

FDA 59

FDA 59

PharmaTimes

FEBRUARY 12, 2024

The platform delivers digitalised patient data to improve clinical trials and development

Patients 101

Patients 101

Contrarian Sales Techniques

FEBRUARY 12, 2024

NAPSRx stands for the National Association of Pharmaceutical Sales Representatives®, and it's basically a cool club for folks who want to rock the pharmaceutical sales world. They offer this certification called CNPR, short for Certified National Pharmaceutical Representative, which is like a golden ticket if you're new to the scene or looking to step up your game in pharma sales.

Sales 52

Sales Pharma Pharmaceutical Sales Ethics 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales